Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2024

Open Access 01-12-2024 | Gaucher Disease | Research article

GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice

Authors: Ilaria Gregorio, Loris Russo, Enrica Torretta, Pietro Barbacini, Gabriella Contarini, Giada Pacinelli, Dario Bizzotto, Manuela Moriggi, Paola Braghetta, Francesco Papaleo, Cecilia Gelfi, Enrico Moro, Matilde Cescon

Published in: Molecular Neurodegeneration | Issue 1/2024

Login to get access

Abstract

Background

Mutations in the β-glucocerebrosidase (GBA1) gene do cause the lysosomal storage Gaucher disease (GD) and are among the most frequent genetic risk factors for Parkinson’s disease (PD). So far, studies on both neuronopathic GD and PD primarily focused on neuronal manifestations, besides the evaluation of microglial and astrocyte implication. White matter alterations were described in the central nervous system of paediatric type 1 GD patients and were suggested to sustain or even play a role in the PD process, although the contribution of oligodendrocytes has been so far scarcely investigated.

Methods

We exploited a system to study the induction of central myelination in vitro, consisting of Oli-neu cells treated with dibutyryl-cAMP, in order to evaluate the expression levels and function of β-glucocerebrosidase during oligodendrocyte differentiation. Conduritol-B-epoxide, a β-glucocerebrosidase irreversible inhibitor was used to dissect the impact of β-glucocerebrosidase inactivation in the process of myelination, lysosomal degradation and α-synuclein accumulation in vitro. Moreover, to study the role of β-glucocerebrosidase in the white matter in vivo, we developed a novel mouse transgenic line in which β-glucocerebrosidase function is abolished in myelinating glia, by crossing the Cnp1-cre mouse line with a line bearing loxP sequences flanking Gba1 exons 9–11, encoding for β-glucocerebrosidase catalytic domain. Immunofluorescence, western blot and lipidomic analyses were performed in brain samples from wild-type and knockout animals in order to assess the impact of genetic inactivation of β-glucocerebrosidase on myelination and on the onset of early neurodegenerative hallmarks, together with differentiation analysis in primary oligodendrocyte cultures.

Results

Here we show that β-glucocerebrosidase inactivation in oligodendrocytes induces lysosomal dysfunction and inhibits myelination in vitro. Moreover, oligodendrocyte-specific β-glucocerebrosidase loss-of-function was sufficient to induce in vivo demyelination and early neurodegenerative hallmarks, including axonal degeneration, α-synuclein accumulation and astrogliosis, together with brain lipid dyshomeostasis and functional impairment.

Conclusions

Our study sheds light on the contribution of oligodendrocytes in GBA1-related diseases and supports the need for better characterizing oligodendrocytes as actors playing a role in neurodegenerative diseases, also pointing at them as potential novel targets to set a brake to disease progression.
Appendix
Available only for authorised users
Literature
1.
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A Review of Gaucher Disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.CrossRefPubMedPubMedCentral
2.
3.
Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher Disease: clinical, biological and therapeutic aspects. Pathobiology. 2015;83:13–23.CrossRefPubMed
4.
Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020;43:1056–9.CrossRefPubMedPubMedCentral
5.
6.
Orvisky E, Park J k, Parker A, Walker J m, Martin B m, Stubblefield B k, et al. The identification of eight novel glucocerebrosidase (GBA) mutations in patients with Gaucher disease. Hum Mutat. 2002;19:458–9.CrossRefPubMed
7.
Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis. 2003;14:595–601.CrossRefPubMed
8.
Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192–207.CrossRefPubMed
9.
Farfel-Becker T, Vitner EB, Pressey SNR, Eilam R, Cooper JD, Futerman AH. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet. 2011;20:1375–86.CrossRefPubMed
10.
Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum Mol Genet. 2014;23:843–54.CrossRefPubMed
11.
Stoker TB, Torsney KM, Barker RA. Pathological mechanisms and clinical aspects of GBA1 mutation-associated Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Park Dis Pathog Clin Asp [Internet]. Brisbane (AU): Codon Publications; 2018 [cited 2023 Feb 20]. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK536716/​
12.
Alaei MR, Tabrizi A, Jafari N, Mozafari H. Gaucher Disease: new expanded classification emphasizing neurological features. Iran J Child Neurol. 2019;13:7–24.PubMedPubMedCentral
13.
Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70:2277–83.CrossRefPubMed
14.
Blumenreich S, Jenkins BJ, Barav OB, Milenkovic I, Futerman AH. The Lysosome and Nonmotor Symptoms: linking Parkinson’s Disease and lysosomal storage disorders. Mov Disord. 2020;35:2150–5.CrossRefPubMed
15.
Pitcairn C, Wani WY, Mazzulli JR. Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson’s disease. Neurobiol Dis. 2019;122:72–82.CrossRefPubMed
16.
Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al. Mitochondria and quality control defects in a mouse model of Gaucher Disease—Links to Parkinson’s Disease. Cell Metab. 2013;17:941–53.CrossRefPubMedPubMedCentral
17.
Rocha EM, Smith GA, Park E, Cao H, Graham A-R, Brown E, et al. Sustained systemic glucocerebrosidase inhibition induces brain α-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid Redox Signal. 2015;23:550–64.CrossRefPubMedPubMedCentral
18.
Awad O, Sarkar C, Panicker LM, Miller D, Zeng X, Sgambato JA, et al. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum Mol Genet. 2015;24:5775–88.CrossRefPubMed
19.
Schöndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014;5:4028.CrossRefADSPubMed
20.
Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher’s Disease Glucocerebrosidase and <alpha>-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37–52.CrossRefPubMedPubMedCentral
21.
Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord. 2011;26:1049–55.CrossRefPubMed
22.
Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, López-González MJ, Dovero S, et al. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Hum Mol Genet. 2017;26:2603–15.CrossRefPubMed
23.
Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A. Neuropathology of the Norrbottnian type of Gaucher disease. Acta Neuropathol (Berl). 1984;65:99–109.CrossRefPubMed
24.
Sanyal A, Novis HS, Gasser E, Lin S, LaVoie MJ. LRRK2 kinase inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-derived neurons. Front Neurosci. 2020;14:442.CrossRefPubMedPubMedCentral
25.
Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E. A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson’s disease. Neurobiol Dis. 2020;134: 104647.CrossRefPubMed
26.
Brunialti E, Villa A, Mekhaeil M, Mornata F, Vegeto E, Maggi A, et al. Inhibition of microglial β-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons. J Neuroinflammation. 2021;18:220.CrossRefPubMedPubMedCentral
27.
Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen T-H, et al. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Zaidi M, editor eLife. 2022;11:e79830.
28.
Wang L, Lin G, Zuo Z, Li Y, Byeon SK, Pandey A, et al. Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia. Sci Adv. 8:eabn3326.
29.
30.
Meschkat M, Steyer AM, Weil M-T, Kusch K, Jahn O, Piepkorn L, et al. White matter integrity in mice requires continuous myelin synthesis at the inner tongue. Nat Commun. 2022;13:1163.CrossRefADSPubMedPubMedCentral
31.
Edgar JM, McGowan E, Chapple KJ, Möbius W, Lemgruber L, Insall RH, et al. Río-Hortega’s drawings revisited with fluorescent protein defines a cytoplasm-filled channel system of CNS myelin. J Anat. 2021;239:1241–55.CrossRefPubMedPubMedCentral
32.
Kang H, Zhang M, Ouyang M, Guo R, Yu Q, Peng Q, et al. Brain white matter microstructural alterations in children of type I Gaucher disease characterized with diffusion tensor MR imaging. Eur J Radiol. 2018;102:22–9.CrossRefPubMed
33.
Davies EH, Seunarine KK, Banks T, Clark CA, Vellodi A. Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging. J Inherit Metab Dis. 2011;34:549–53.CrossRefPubMed
34.
Aronson SM, Volk BW. Cerebral Sphingolipidoses: a symposium on Tay-Sachs’ Disease and allied disorders. Elsevier; 2013. p. 1–474. ISBN: 9781483221519.
35.
36.
Enquist IB, Nilsson E, Ooka A, Månsson J-E, Olsson K, Ehinger M, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A. 2006;103:13819–24.CrossRefADSPubMedPubMedCentral
37.
Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet. 2003;33:366–74.CrossRefPubMed
38.
Chen P, Cescon M, Megighian A, Ronaldo P. Collagen VI regulates peripheral nerve myelination and function. FASEB J. 2014;28:1145–56.CrossRefPubMed
39.
Jung M, Krämer E, Grzenkowski M, Tang K, Blakemore W, Aguzzi A, et al. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur J Neurosci. 1995;7:1245–65.CrossRefPubMed
40.
Trotter J, Bitter-Suermann D, Schachner M. Differentiation-regulated loss of the polysialylated embryonic form and expression of the different polypeptides of the neural cell adhesion molecule by cultured oligodendrocytes and myelin. J Neurosci Res. 1989;22:369–83.CrossRefPubMed
41.
Zoupi L, Savvaki M, Kalemaki K, Kalafatakis I, Sidiropoulou K, Karagogeos D. The function of contactin-2/TAG-1 in oligodendrocytes in health and demyelinating pathology. Glia. 2018;66:576–91.CrossRefPubMed
42.
Sasaki A, Arawaka S, Sato H, Kato T. Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces. Sci Rep. 2015;5:14211.CrossRefADSPubMedPubMedCentral
43.
Thetiot M, Freeman SA, Desmazières A. Immunohistochemical analysis of myelin structures. In: Woodhoo A, editor. Myelin Methods Protoc. New York, NY: Springer; 2018. p. 15–23.CrossRef
44.
He D, Marie C, Zhao C, Kim B, Wang J, Deng Y, et al. Chd7 Cooperates with Sox10 and Regulates the Onset of CNS Myelination and Remyelination. Nat Neurosci. 2016;19:678–89.CrossRefPubMedPubMedCentral
45.
de Faria O, Dhaunchak AS, Kamen Y, Roth AD, Kuhlmann T, Colman DR, et al. TMEM10 promotes oligodendrocyte differentiation and is expressed by oligodendrocytes in human remyelinating multiple sclerosis plaques. Sci Rep. 2019;9:3606.CrossRefADSPubMedPubMedCentral
46.
47.
García-Mateo N, Pascua-Maestro R, Pérez-Castellanos A, Lillo C, Sanchez D, Ganfornina MD. Myelin extracellular leaflet compaction requires apolipoprotein D membrane management to optimize lysosomal-dependent recycling and glycocalyx removal. Glia. 2018;66:670–87.CrossRefPubMed
48.
Magalhaes J, Gegg ME, Migdalska-Richards A, Doherty MK, Whitfield PD, Schapira AHV. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet. 2016;25:3432–45.CrossRefPubMedPubMedCentral
49.
Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s Disease. Cell Tissue Res. 2018;373:51–60.CrossRefPubMed
50.
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-Sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–47.CrossRefPubMedPubMedCentral
51.
Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62:964–70.CrossRefPubMedPubMedCentral
52.
Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab. 2007;92:336–45.CrossRefPubMed
53.
García-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodríguez-Traver E, Kulisevsky J, et al. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson’s disease. Mov Disord. 2017;32:1409–22.CrossRefPubMed
54.
Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:56–66.CrossRefPubMed
55.
Jäkel S, Dimou L. Glial cells and their function in the adult brain: a journey through the history of their ablation. Front Cell Neurosci. 2017;11:24.CrossRefPubMedPubMedCentral
56.
Montero-Odasso M, Pieruccini-Faria F, Bartha R, Black SE, Finger E, Freedman M, et al. Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the ontario neurodegenerative research initiative (ONDRI). J Alzheimer Dis. 2017;59:707–21.
57.
McNeill A, Duran R, Proukakis C, Bras J, Hughes D, Mehta A, et al. Hyposmia and cognitive impairment in Gaucher Disease patients and carriers. Mov Disord Off J Mov Disord Soc. 2012;27:526–32.CrossRef
58.
Gegg ME, Burke D, Heales SJR, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson Disease brains. Ann Neurol. 2012;72:455–63.CrossRefPubMedPubMedCentral
59.
Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. Npj Park Dis. 2022;8:1–15.
60.
Trajkovic K, Dhaunchak AS, Goncalves JT, Wenzel D, Schneider A, Bunt G, et al. Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites. J Cell Biol. 2006;172:937–48.CrossRefPubMedPubMedCentral
61.
Winterstein C, Trotter J, Krämer-Albers E-M. Distinct endocytic recycling of myelin proteins promotes oligodendroglial membrane remodeling. J Cell Sci. 2008;121:834–42.CrossRefPubMed
62.
Bankston AN, Forston MD, Howard RM, Andres KR, Smith AE, Ohri SS, et al. Autophagy is essential for oligodendrocyte differentiation, survival, and proper myelination. Glia. 2019;67:1745–59.CrossRefPubMed
63.
Folkerth RD. Abnormalities of developing white matter in lysosomal storage diseases. J Neuropathol Exp Neurol. 1999;58:887–902.CrossRefPubMed
64.
65.
Festa LK, Clyde AE, Long CC, Roth LM, Grinspan JB, Jordan-Sciutto KL. Antiretroviral treatment reveals a novel role for lysosomes in oligodendrocyte maturation. J Neurochem. 2023;165:722–40.CrossRefPubMed
66.
Blanchard JW, Akay LA, Davila-Velderrain J, von Maydell D, Mathys H, Davidson SM, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611:769–79.CrossRefADSPubMedPubMedCentral
67.
Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, et al. Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. stem cell Rep. 2015;5:174.CrossRef
68.
May VEL, Ettle B, Poehler A-M, Nuber S, Ubhi K, Rockenstein E, et al. α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging. 2014;35:2357–68.CrossRefPubMedPubMedCentral
69.
Kaji S, Maki T, Kinoshita H, Uemura N, Ayaki T, Kawamoto Y, et al. Pathological endogenous α-synuclein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system atrophy. Stem Cell Rep. 2018;10:356–65.CrossRef
70.
Lee H-J, Khoshaghideh F, Patel S, Lee S-J. Clearance of α-Synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004;24:1888–96.CrossRefPubMedPubMedCentral
71.
Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.CrossRefPubMedPubMedCentral
72.
Ettle B, Reiprich S, Deusser J, Schlachetzki JCM, Xiang W, Prots I, et al. Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci. 2014;0:68–78.CrossRefPubMedCentral
73.
Agosta F, Kostic VS, Davidovic K, Kresojević N, Sarro L, Svetel M, et al. White matter abnormalities in Parkinson’s disease patients with glucocerebrosidase gene mutations. Mov Disord. 2013;28:772–8.CrossRefPubMed
74.
Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, et al. Regional volume analysis of the Parkinson Disease brain in early disease stage: gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol. 2011;32:682–7.CrossRefPubMedPubMedCentral
75.
Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, et al. Cognitive status correlates with white matter alteration in Parkinson’s disease. Hum Brain Mapp. 2011;33:727–39.CrossRefPubMedPubMedCentral
76.
Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, et al. Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson’s disease? Mov Disord. 2016;31:103–10.CrossRefPubMed
77.
Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 1998;280:1610–3.CrossRefADSPubMed
78.
Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485:517–21.CrossRefADSPubMedPubMedCentral
79.
Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443–8.CrossRefADSPubMedPubMedCentral
80.
Fuller M, Futerman AH. The brain lipidome in neurodegenerative lysosomal storage disorders. Biochem Biophys Res Commun. 2018;504:623–8.CrossRefPubMed
81.
Leyns CEG, Prigent A, Beezhold B, Yao L, Hatcher NG, Tao P, et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease. Npj Park Dis. 2023;9:1–14.
82.
Mahoney-Crane CL, Viswanathan M, Russell D, Curtiss RAC, Freire J, Bobba SS, et al. Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions. J Neurosci. 2023;43:501–21.CrossRefPubMedPubMedCentral
83.
Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson’s Disease. J Neurosci. 2017;37:9617–31.CrossRefPubMedPubMedCentral
84.
Deane JE, Graham SC, Kim NN, Stein PE, McNair R, Cachón-González MB, et al. Insights into Krabbe disease from structures of galactocerebrosidase. Proc Natl Acad Sci U S A. 2011;108:15169–73.CrossRefADSPubMedPubMedCentral
85.
86.
Jung W, Liu C, Yu Y, Chang Y, Lien W, Chao H, et al. Lipophagy prevents activity-dependent neurodegeneration due to dihydroceramide accumulation in vivo. EMBO Rep. 2017;18:1150–65.CrossRefPubMedPubMedCentral
87.
Pant DC, Dorboz I, Schluter A, Fourcade S, Launay N, Joya J, et al. Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. J Clin Invest. 2019;129:1240–56.
88.
Shimizu T, Schutt CR, Izumi Y, Tomiyasu N, Omahdi Z, Kano K, et al. Direct activation of microglia by β-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease. Immunity. 2023;56:307-319.e8.CrossRef
89.
Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of α-synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97:92-107.e10.CrossRefPubMed
90.
Paul A, Jacoby G, Laor Bar-Yosef D, Beck R, Gazit E, Segal D. Glucosylceramide associated with Gaucher Disease forms amyloid-like twisted ribbon fibrils that induce α-synuclein Aggregation. ACS Nano. 2021;15:11854–68.CrossRefPubMedPubMedCentral
91.
Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson’s disease. Nat Commun. 2021;12:1807.CrossRefADSPubMedPubMedCentral
92.
Alaamery M, Albesher N, Aljawini N, Alsuwailm M, Massadeh S, Wheeler MA, et al. Role of sphingolipid metabolism in neurodegeneration. J Neurochem. 2021;158:25–35.CrossRefPubMed
93.
Abbott SK, Li H, Muñoz SS, Knoch B, Batterham M, Murphy KE, et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease. Mov Disord. 2014;29:518–26.CrossRefPubMed
94.
Mielke MM, Maetzler W, Haughey NJ, Bandaru VVR, Savica R, Deuschle C, et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s Disease and associated with cognitive impairment: a pilot study. PLoS ONE. 2013;8: e73094.CrossRefADSPubMedPubMedCentral
95.
Pellicano C, Benincasa D, Pisani V, Buttarelli FR, Giovannelli M, Pontieri FE. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr Dis Treat. 2007;3:145–52.CrossRefPubMedPubMedCentral
96.
Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, et al. Motor symptoms in Parkinson’s disease: a unified framework. Neurosci Biobehav Rev. 2016;68:727–40.CrossRefPubMed
97.
Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG. Gait dynamics in mouse models of Parkinson’s disease and Huntington’s disease. J Neuroengineering Rehabil. 2005;2:20.CrossRefPubMedCentral
98.
Dai M, Liou B, Swope B, Wang X, Zhang W, Inskeep V, et al. Progression of behavioral and CNS deficits in a viable murine model of chronic neuronopathic Gaucher Disease. PLoS ONE. 2016;11: e0162367.CrossRefPubMedPubMedCentral
99.
Farfel-Becker T, Do J, Tayebi N, Sidransky E. Can GBA1-associated parkinson disease be modeled in the mouse? Trends Neurosci. 2019;42:631–43.CrossRefPubMed
100.
Fernagut PO, Diguet E, Labattu B, Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods. 2002;113:123–30.CrossRefPubMed
101.
Lamontagne-Proulx J, Coulombe K, Morissette M, Rieux M, Calon F, Di Paolo T, et al. Sex and age differences in a progressive synucleinopathy mouse model. Biomolecules. 2023;13:977.CrossRefPubMedPubMedCentral
102.
Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, et al. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson’s disease model. Brain. 2020;143:249–65.CrossRefPubMed
103.
Prediger RD, Schamne MG, Sampaio TB, Moreira ELG, Rial D. Animal models of olfactory dysfunction in neurodegenerative diseases. Handb Clin Neurol. 2019;164:431–52.CrossRefPubMed
104.
Cerri S, Mus L, Blandini F. Parkinson’s Disease in women and men: what’s the difference? J Park Dis. 2019;9:501–15.
105.
Li Q, Jing Y, Lun P, Liu X, Sun P. Association of gender and age at onset with glucocerebrosidase associated Parkinson’s disease: a systematic review and meta-analysis. Neurol Sci. 2021;42:2261–71.CrossRefPubMed
106.
Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, et al. Clinical and dopamine transporter imaging characteristics of leucine- rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson’s Disease participants in the Parkinson’s Progression Markers Initiative: a cross-sectional study. Mov Disord Off J Mov Disord Soc. 2020;35:833–44.CrossRef
107.
Brunialti E, Villa A, Toffoli M, Lucas Del Pozo S, Rizzi N, Meda C, et al. sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-Linked Parkinson’s Disease. Cells. 2023;12:343.CrossRefPubMedPubMedCentral
Metadata
Title
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice
Authors
Ilaria Gregorio
Loris Russo
Enrica Torretta
Pietro Barbacini
Gabriella Contarini
Giada Pacinelli
Dario Bizzotto
Manuela Moriggi
Paola Braghetta
Francesco Papaleo
Cecilia Gelfi
Enrico Moro
Matilde Cescon
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2024
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/s13024-024-00713-z

Other articles of this Issue 1/2024

Molecular Neurodegeneration 1/2024 Go to the issue

Research article

Cognitive, functional, and neuropsychiatric correlates of regional tau pathology in autopsy-confirmed chronic traumatic encephalopathy

Review

Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration

Research article

Rejuvenating aged microglia by p16ink4a-siRNA-loaded nanoparticles increases amyloid-β clearance in animal models of Alzheimer’s disease

Research article

Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology

Research article

A partial Drp1 knockout improves autophagy flux independent of mitochondrial function

Research article

Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer’s disease